TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer
Status:
Not yet recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
TST001 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. This
is an open-label, single-arm phase II study to evaluate the efficacy and safety of TST001 for
patients with CLDN18.2 positive previously treated unresectable advanced or metastatic
Biliary Tract Cancer.